Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy

Cardiovascular Research

Volumn 99, Issue 4, 2013, Pages 760-768

  Iwata, Yuko ^a   Ohtake, Hitomi ^a   Suzuki, Osamu ^b   Matsuda, Junichiro ^b   Komamura, Kazuo ^c   Wakabayashi, Shigeo ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Ca 2+ permeable channel; Dilated cardiomyopathy; DOX induced cardiomyopathy; Heart failure; Therapeutic tool

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DELTA SARCOGLYCAN; DOXORUBICIN; REACTIVE OXYGEN METABOLITE; VANILLOID RECEPTOR 2;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; FIBROSIS; HAMSTER; HEART FAILURE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOLEMMA; TRANSGENIC MOUSE;

CA2+-PERMEABLE CHANNEL; DILATED CARDIOMYOPATHY; DOX-INDUCED CARDIOMYOPATHY; HEART FAILURE; THERAPEUTIC TOOL;

ANIMALS; BORON COMPOUNDS; CALCIUM; CALCIUM CHANNELS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMYOPATHY, DILATED; CRICETINAE; DISEASE PROGRESSION; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORTHO-AMINOBENZOATES; SARCOLEMMA; TRPV CATION CHANNELS;

EID: 84883251517     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt163     Document Type: Article

References (38)

1. Hughes SE, McKenna WJ. New insights into the pathology of inherited cardiomyopathy. Heart 2005;91:257-264.
2. Fatkin D, Graham RM. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 2002;82:945-980.
3. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-567.
4. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010;375:752-762.
5. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature 1989;338:259-262.
6. Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, Politano L et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997;6:601-607.
7. Jeong EM, Liu M, Sturdy M,Gao G, VargheseST, SovariAAet al. Metabolic stress, reactive oxygen species, and arrhythmia. J Mol Cell Cardiol 2012;52:454-463.
8. Toko H, Takahashi H, Kayama Y, Oka T, Minamino T, Okada S et al. Ca2+/calmodulindependent kinase IIdelta causes heart failure by accumulation of p53 in dilated cardiomyopathy. Circulation 2010;122:891-899.
9. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85: 1046-1055.
10. Lindner M, BrandtMC, Sauer H, Hescheler J, BohleT, Beuckelmann DJ. Calcium sparks in human ventricular cardiomyocytes from patients with terminal heart failure. Cell Calcium 2002;31:175-182.
11. Louch WE, Bito V, Heinzel FR, Macianskiene R, Vanhaecke J, FlamengWet al. Reduced synchrony ofCa2+release with loss of T-tubules-A comparison toCa2+release inhuman failing cardiomyocytes. Cardiovascular Research 2004;62:63-73.
12. Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Circ Res 2011; 108:265-272.
13. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev 2007;87:165-217.
14. Watanabe H, Murakami M, Ohba T, Takahashi Y, Ito H. TRP channel and cardiovascular disease. Pharmacol Therap 2008;118:337-351.
15. Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel. J Cell Biol 2003;161:957-967.
16. Suzuki O, Kanai T, Nishikawa T, Yamamoto Y, Noguchi A, Takimoto K et al. Adult onset cardiac dilatation in a transgenicmouse line with Galb1,3GalNAca2,3-sialyltransferase II (ST3Gal-II) transgenes: a new model for dilated cardiomyopathy. Proc Japan Acad, SerB 2011;87:550-562.
17. Iwata Y, Katanosaka Y, Arai Y, Shigekawa M,Wakabayashi S. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum Mol Genet 2009;18:824-834.
18. Iwata Y, Pan Y, Hanada H, Yoshida T, Shigekawa M. Dystrophin-glycoprotein complex purified from hamster cardiac muscle. Comparison of the complexes from cardiac and skeletal muscles of hamster and rabbit. J Mol Cell Cardiol 1996;28:2501-2509.
19. Nakamura TY, Iwata Y, Arai Y, Komamura K,Wakabayashi S. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+signals that induce cardiac hypertrophy and heart failure. Circ Res 2008;103:891-899.
20. Hu HZ, Gu Q, Wang C, Colton CK, Tang J, Kinoshita-Kawada M et al. 2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem 2004;279:35741-35748.
21. Lievremont JP, Bird GS, Putney JW Jr. Mechanism of inhibition of TRPC cation channels by 2-aminoethoxydiphenylborane. Mol Pharmacol 2005;68:758-762.
22. Iwata Y, Katanosaka Y, Shijun Z, Kobayashi Y, Hanada H, Shigekawa M et al. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol 2005;70:740-751.
23. Mihara H, Boudaka A, Shibasaki K, Yamanaka A, SugiyamaT, Tominaga M. Involvement of TRPV2 activation in intestinal movement through nitric oxide production in mice. J Neurosci 2010;30:16536-16544.
24. Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD et al. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res 2012;111:131-150.
25. Anderson ME. CaMKII and a failing strategy for growth in heart. J Clin Invest 2009;119: 1082-1085.
26. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115: 500-508.
27. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, PlankDMet al.Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004; 94:110-118.
28. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al. A calcineurindependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
29. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004;322:1178-1191.
30. Hwang JJ, Allen PD, Tseng GC, Lam CW, Fananapazir L, Dzau VJ et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genom 2002;10:31-44.
31. Toyo-Oka T, Kawada T, Nakata J, Xie H, Urabe M, Masui F et al. Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. Proc Natl Acad Sci USA 2004;101:7381-7385.
32. Kanzaki M, Zhang YQ, Mashima H, Li L, Shibata H, Kojima I. Translocation of a calciumpermeable cation channel induced by insulin-like growth factor-I. Nat Cell Biol 1999;1: 165-170.
33. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 2000;47:23-37.
34. O'QuinnMP, Palatinus JA, Harris BS, HewettKW, Gourdie RG.Apeptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circ Res 2011;108:704-715.
35. Pae HO, Jeong SO, Koo BS, Ha HY, Lee KM, Chung HT. Tranilast, an orally active antiallergic drug, up-regulates the anti-inflammatory heme oxygenase-1 expression but down-regulates the pro-inflammatory cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW264.7 macrophages. Biochem Biophys Res Commun 2008;371: 361-365.
36. Kelly DJ, ZhangY, Connelly K,CoxAJ, Martin J,KrumHet al.Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H2860-H2869.
37. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 2002;195: 375-381.
38. Zhang D, Spielmann A, Wang L, Ding G, Huang F, Gu Q et al. Mast-cell degranulation induced by physical stimuli involves the activation of transient-receptor-potential channel TRPV2. Physiol Res 2012;61:113-124.